Por: New York Post Life March 28, 2023
The future of cancer treatment — hailed as the “holy grail” of early detection — is now being put to the test. Following a radically successful trial on cancer patients, a new blood test that promises to predict tumors more than a year before they begin to form is now being applied in hospitals across the United Kingdom. “This is the first pan-cancer blood test,” said Ashish Tripathi, founder and CEO of Tzar Labs as well as chairman... + full article
The New York Times USA Business April 03, 2023
The Federal Trade Commission on Monday ordered Illumina, the leading maker of gene-sequencing machines, to divest Grail, a cancer-test developer.The move by the F.T.C. is the latest development in a case seen by antitrust experts as a to stop big companies from buying fledgling... + más
FTC orders Illumina to unwind $7B deal for cancer test developer Grail | Fox Business
Biotech company Illumina pushes back against Carl Icahn’s proxy fight over $7.1 billion Grail deal | CNBC
Fox Business USA Business April 03, 2023
Check out whats clicking on FoxBusiness.com The on Monday ordered life sciences company Illumina to unwind its $7.1 billion acquisition of cancer detection test developer Grail Inc., citing antitrust concerns. The commission voted unanimously in a 4-0 decision to force Illumina... + más
F.T.C. Orders Gene-Sequencing Company Illumina to Divest Acquisition | The New York Times
CNBC USA Health March 24, 2023
In this articleCarl Icahn speaking at Delivering Alpha in New York on Sept. 13, 2016.David A. Grogan CNBCCarl Icahn on Friday alleged that 's directors demanded extra personal liability insurance before the biotech company signed off on a $7.1 billion acquisition of cancer... + más
Icahn proposes three candidates for Illumina’s board — Here’s what could be next in the battle | CNBC
CNBC USA Health March 21, 2023
In this articleCarl IcahnAdam Jeffery CNBC Biotech company pushed back Monday against Carl Icahn's proxy fight over the company's acquisition of cancer test developer Grail, saying the activist investor's board nominees do not add value. The San Diego-based DNA... + más
Carl Icahn claims Illumina directors got extra insurance to close 'disastrous' $7.1 billion Grail deal | CNBC
CNBC USA Business March 18, 2023
Business: develops, manufactures and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and Grail. Grail, which was acquired in , is a health-care company focused on early detection of... + más
The Boston Globe USA Business October 25, 2022
Our best weapon against cancer may already live inside us — it just needs a little prodding. That’s the premise behind Normunity, which launched Tuesday with $65 million from investors to develop a suite of drugs that it dubs “immune normalizers” to help restore the... + más
A New Approach to Spotting Tumors: Look for Their Microbes | The New York Times
A Devious Cellular Trick Cancers Can Use to Escape Your Immune System | The New York Times
The New York Times USA Science September 29, 2022
Look up an image of a tumor on Google, and you’ll probably end up with a brightly colored cluster of cancer cells on a drab background of healthy tissue. But for Lian Narunsky Haziza, a cancer biologist at the Weizmann Institute of Science in Israel, the picture looks very... + más
Should We Be Searching for Smart Aliens or Dumb Aliens? | The Atlantic
About iurex | Privacy Policy | Disclaimer |